FDA Accepts NDA for Lorundrostat for Hypertension; Sets PDUFA Date and Reports Mixed OSA Trial Results

summarizeSummary

Mineralys Therapeutics announced FDA acceptance of its New Drug Application for lorundrostat for hypertension, setting a PDUFA target date of December 22, 2026, while also reporting mixed Phase 2 results for obstructive sleep apnea.

check_boxKey Events

• NDA Accepted for Hypertension

  The FDA has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.

• PDUFA Target Date Set

  The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026, for lorundrostat.

• Mixed Phase 2 Explore-OSA Trial Results

  The exploratory Phase 2 Explore-OSA trial did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index (AHI), its primary endpoint. However, it showed a significant 6.2 mmHg placebo-adjusted reduction in blood pressure and a favorable safety profile in participants with difficult-to-control hypertension and OSA.

auto_awesomeAnalysis

The FDA's acceptance of the New Drug Application (NDA) for lorundrostat for hypertension is a critical milestone, significantly advancing the company's lead candidate towards potential market approval. The assigned PDUFA target action date provides a clear timeline for investors. While the Phase 2 Explore-OSA trial did not meet its primary endpoint for reducing the apnea-hypopnea index (AHI), it did demonstrate a clinically meaningful reduction in blood pressure and a favorable safety profile in a difficult-to-treat hypertensive population. This reinforces lorundrostat's efficacy in hypertension, which is the focus of the NDA, despite the setback for the OSA indication. Investors should monitor the FDA review process and future updates on the OSA program.